Concepts (250)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 14 | 2025 | 708 | 4.050 |
Why?
|
| Opioid-Related Disorders | 8 | 2026 | 174 | 2.710 |
Why?
|
| Analgesics, Opioid | 6 | 2026 | 239 | 1.960 |
Why?
|
| Vaccination | 13 | 2024 | 725 | 1.890 |
Why?
|
| Wounds, Gunshot | 2 | 2024 | 18 | 1.630 |
Why?
|
| Pre-Exposure Prophylaxis | 3 | 2023 | 20 | 1.590 |
Why?
|
| Cancer Survivors | 2 | 2025 | 114 | 1.580 |
Why?
|
| Humans | 61 | 2026 | 16832 | 1.550 |
Why?
|
| Adult | 35 | 2026 | 7255 | 1.550 |
Why?
|
| Male | 46 | 2026 | 9556 | 1.500 |
Why?
|
| California | 24 | 2025 | 2244 | 1.430 |
Why?
|
| Female | 47 | 2026 | 12193 | 1.320 |
Why?
|
| Anti-HIV Agents | 2 | 2023 | 163 | 1.310 |
Why?
|
| Middle Aged | 31 | 2026 | 7515 | 1.240 |
Why?
|
| Vaccines | 6 | 2022 | 225 | 1.180 |
Why?
|
| Delivery of Health Care, Integrated | 4 | 2022 | 515 | 1.170 |
Why?
|
| Adolescent | 23 | 2025 | 3464 | 1.170 |
Why?
|
| Herpes Zoster Vaccine | 5 | 2017 | 60 | 1.160 |
Why?
|
| Electronic Health Records | 5 | 2024 | 702 | 1.140 |
Why?
|
| Retrospective Studies | 21 | 2025 | 2463 | 1.140 |
Why?
|
| Managed Care Programs | 6 | 2017 | 275 | 1.040 |
Why?
|
| Firearms | 2 | 2024 | 32 | 0.980 |
Why?
|
| Young Adult | 19 | 2025 | 2456 | 0.960 |
Why?
|
| Papillomavirus Vaccines | 6 | 2022 | 113 | 0.940 |
Why?
|
| Aged | 21 | 2026 | 5901 | 0.940 |
Why?
|
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 5 | 2017 | 31 | 0.920 |
Why?
|
| Cohort Studies | 19 | 2026 | 2396 | 0.900 |
Why?
|
| Sexual and Gender Minorities | 1 | 2025 | 32 | 0.870 |
Why?
|
| Neoplasms | 3 | 2025 | 447 | 0.860 |
Why?
|
| Sexual Behavior | 1 | 2025 | 112 | 0.840 |
Why?
|
| Community Health Centers | 1 | 2024 | 58 | 0.820 |
Why?
|
| Machine Learning | 1 | 2024 | 60 | 0.810 |
Why?
|
| Chronic Pain | 2 | 2022 | 125 | 0.800 |
Why?
|
| Chickenpox Vaccine | 3 | 2015 | 91 | 0.770 |
Why?
|
| Health Behavior | 1 | 2025 | 332 | 0.770 |
Why?
|
| Papillomavirus Infections | 6 | 2022 | 141 | 0.770 |
Why?
|
| Vaccination Coverage | 1 | 2024 | 68 | 0.770 |
Why?
|
| Fractures, Bone | 1 | 2023 | 92 | 0.760 |
Why?
|
| Immunization, Secondary | 3 | 2016 | 58 | 0.720 |
Why?
|
| Chickenpox | 2 | 2012 | 35 | 0.690 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 155 | 0.690 |
Why?
|
| United States | 16 | 2026 | 3858 | 0.670 |
Why?
|
| Herpes Zoster | 4 | 2016 | 80 | 0.660 |
Why?
|
| Suicidal Ideation | 1 | 2022 | 98 | 0.660 |
Why?
|
| Incidence | 6 | 2026 | 1229 | 0.590 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 4 | 2019 | 97 | 0.570 |
Why?
|
| Hypertension | 1 | 2023 | 475 | 0.570 |
Why?
|
| Risk Factors | 10 | 2025 | 3108 | 0.560 |
Why?
|
| Hospitalization | 6 | 2025 | 816 | 0.550 |
Why?
|
| Electronics, Medical | 1 | 2018 | 3 | 0.540 |
Why?
|
| Breast Neoplasms | 1 | 2025 | 913 | 0.520 |
Why?
|
| Buprenorphine | 3 | 2025 | 50 | 0.520 |
Why?
|
| Medicare Part D | 1 | 2017 | 17 | 0.520 |
Why?
|
| Cost Sharing | 1 | 2017 | 28 | 0.510 |
Why?
|
| Coinfection | 2 | 2019 | 28 | 0.500 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2017 | 104 | 0.490 |
Why?
|
| Age Factors | 5 | 2025 | 814 | 0.460 |
Why?
|
| Primary Health Care | 4 | 2021 | 693 | 0.440 |
Why?
|
| Influenza Vaccines | 4 | 2019 | 300 | 0.430 |
Why?
|
| Viral Load | 3 | 2021 | 141 | 0.430 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2015 | 353 | 0.430 |
Why?
|
| Child | 13 | 2022 | 2433 | 0.430 |
Why?
|
| Tenofovir | 2 | 2023 | 18 | 0.400 |
Why?
|
| Hepatitis B | 1 | 2014 | 43 | 0.400 |
Why?
|
| Preventive Medicine | 1 | 2013 | 21 | 0.390 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2013 | 53 | 0.380 |
Why?
|
| Drug Utilization | 1 | 2013 | 112 | 0.380 |
Why?
|
| Mothers | 1 | 2013 | 104 | 0.370 |
Why?
|
| Herpesvirus 2, Human | 1 | 2012 | 3 | 0.360 |
Why?
|
| Herpes Simplex | 1 | 2012 | 7 | 0.360 |
Why?
|
| Pneumococcal Infections | 1 | 2012 | 43 | 0.360 |
Why?
|
| Pneumococcal Vaccines | 1 | 2012 | 67 | 0.350 |
Why?
|
| Databases, Factual | 1 | 2012 | 294 | 0.340 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2022 | 182 | 0.340 |
Why?
|
| Coronary Artery Disease | 1 | 2012 | 79 | 0.340 |
Why?
|
| Abortion, Spontaneous | 3 | 2021 | 49 | 0.340 |
Why?
|
| Risk Assessment | 4 | 2024 | 1047 | 0.330 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2023 | 290 | 0.330 |
Why?
|
| Antiviral Agents | 2 | 2025 | 92 | 0.320 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 1887 | 0.320 |
Why?
|
| Seizures, Febrile | 3 | 2015 | 42 | 0.310 |
Why?
|
| Opiate Substitution Treatment | 3 | 2025 | 53 | 0.290 |
Why?
|
| Vaccines, Inactivated | 2 | 2019 | 73 | 0.290 |
Why?
|
| Meningococcal Vaccines | 3 | 2022 | 40 | 0.290 |
Why?
|
| Child, Preschool | 7 | 2017 | 1430 | 0.280 |
Why?
|
| Influenza, Human | 2 | 2025 | 292 | 0.270 |
Why?
|
| Proportional Hazards Models | 4 | 2025 | 657 | 0.270 |
Why?
|
| Hepatitis C | 2 | 2021 | 54 | 0.270 |
Why?
|
| Adenosine Monophosphate | 1 | 2025 | 6 | 0.230 |
Why?
|
| Alanine | 1 | 2025 | 8 | 0.230 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2018 | 158 | 0.230 |
Why?
|
| Head and Neck Neoplasms | 1 | 2025 | 8 | 0.230 |
Why?
|
| Survivorship | 1 | 2025 | 13 | 0.220 |
Why?
|
| Home Care Services | 1 | 2025 | 35 | 0.220 |
Why?
|
| Benzodiazepines | 1 | 2025 | 27 | 0.220 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 1233 | 0.220 |
Why?
|
| Narcotic Antagonists | 1 | 2025 | 23 | 0.220 |
Why?
|
| Self-Injurious Behavior | 1 | 2025 | 45 | 0.210 |
Why?
|
| Comorbidity | 3 | 2021 | 516 | 0.210 |
Why?
|
| Hepatitis B Vaccines | 2 | 2014 | 44 | 0.200 |
Why?
|
| Self Report | 1 | 2025 | 248 | 0.200 |
Why?
|
| Radiculopathy | 1 | 2023 | 5 | 0.200 |
Why?
|
| Fumarates | 1 | 2023 | 4 | 0.200 |
Why?
|
| Adenine | 1 | 2023 | 8 | 0.200 |
Why?
|
| Health Status | 1 | 2025 | 256 | 0.200 |
Why?
|
| Musculoskeletal Pain | 1 | 2023 | 26 | 0.200 |
Why?
|
| Age Distribution | 1 | 2023 | 221 | 0.190 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2022 | 4 | 0.190 |
Why?
|
| Odds Ratio | 4 | 2025 | 569 | 0.190 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 129 | 0.190 |
Why?
|
| Infant | 6 | 2018 | 1212 | 0.180 |
Why?
|
| Premature Birth | 2 | 2021 | 133 | 0.180 |
Why?
|
| Immunization Schedule | 2 | 2022 | 127 | 0.180 |
Why?
|
| Kidney Failure, Chronic | 2 | 2015 | 144 | 0.180 |
Why?
|
| Drug Prescriptions | 1 | 2022 | 137 | 0.180 |
Why?
|
| Vaccines, Combined | 2 | 2019 | 80 | 0.170 |
Why?
|
| Suicide, Attempted | 1 | 2022 | 92 | 0.170 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 2 | 2022 | 98 | 0.160 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 374 | 0.160 |
Why?
|
| Algorithms | 1 | 2022 | 210 | 0.160 |
Why?
|
| Life Expectancy | 1 | 2020 | 33 | 0.160 |
Why?
|
| Epidemiological Monitoring | 1 | 2019 | 21 | 0.150 |
Why?
|
| Prescription Drugs | 1 | 2020 | 29 | 0.150 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 1 | 2019 | 3 | 0.150 |
Why?
|
| Disease Transmission, Infectious | 1 | 2019 | 12 | 0.150 |
Why?
|
| Logistic Models | 3 | 2025 | 796 | 0.150 |
Why?
|
| Risk | 2 | 2018 | 453 | 0.150 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 29 | 0.150 |
Why?
|
| Depressive Disorder, Major | 1 | 2020 | 95 | 0.140 |
Why?
|
| Patient Compliance | 2 | 2025 | 262 | 0.140 |
Why?
|
| Infant Mortality | 1 | 2018 | 14 | 0.140 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2017 | 10 | 0.130 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 489 | 0.130 |
Why?
|
| Preconception Care | 1 | 2017 | 43 | 0.130 |
Why?
|
| Heart Failure | 1 | 2022 | 403 | 0.130 |
Why?
|
| Meningitis, Meningococcal | 1 | 2017 | 6 | 0.130 |
Why?
|
| Anus Neoplasms | 1 | 2017 | 28 | 0.120 |
Why?
|
| Papillomaviridae | 1 | 2017 | 58 | 0.120 |
Why?
|
| Alcoholism | 1 | 2019 | 235 | 0.120 |
Why?
|
| Stroke | 1 | 2019 | 297 | 0.120 |
Why?
|
| Time Factors | 3 | 2016 | 989 | 0.120 |
Why?
|
| Perioperative Period | 1 | 2016 | 5 | 0.120 |
Why?
|
| Prenatal Care | 1 | 2017 | 123 | 0.120 |
Why?
|
| Policy Making | 1 | 2016 | 14 | 0.120 |
Why?
|
| Interferon-alpha | 1 | 2015 | 1 | 0.110 |
Why?
|
| Sex Factors | 2 | 2015 | 560 | 0.110 |
Why?
|
| Poisson Distribution | 1 | 2015 | 84 | 0.110 |
Why?
|
| Ribavirin | 1 | 2015 | 6 | 0.110 |
Why?
|
| Mass Screening | 1 | 2021 | 670 | 0.110 |
Why?
|
| Hepacivirus | 1 | 2015 | 41 | 0.110 |
Why?
|
| Surveys and Questionnaires | 2 | 2025 | 1204 | 0.110 |
Why?
|
| African Americans | 2 | 2017 | 394 | 0.110 |
Why?
|
| Ethnic Groups | 3 | 2014 | 418 | 0.110 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2014 | 7 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2016 | 242 | 0.100 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2015 | 64 | 0.100 |
Why?
|
| Hepatitis B Antibodies | 1 | 2014 | 6 | 0.100 |
Why?
|
| Serologic Tests | 1 | 2014 | 6 | 0.100 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2014 | 14 | 0.100 |
Why?
|
| Hepatitis B virus | 1 | 2014 | 22 | 0.100 |
Why?
|
| Chlamydia Infections | 1 | 2014 | 24 | 0.100 |
Why?
|
| Gonorrhea | 1 | 2014 | 20 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 58 | 0.100 |
Why?
|
| Syphilis | 1 | 2014 | 18 | 0.100 |
Why?
|
| Health Maintenance Organizations | 1 | 2015 | 358 | 0.100 |
Why?
|
| Condylomata Acuminata | 1 | 2013 | 16 | 0.100 |
Why?
|
| Quality Control | 1 | 2012 | 37 | 0.090 |
Why?
|
| Multiple Sclerosis | 1 | 2014 | 98 | 0.090 |
Why?
|
| Men's Health | 1 | 2012 | 14 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2025 | 1098 | 0.090 |
Why?
|
| Coronary Angiography | 1 | 2012 | 16 | 0.090 |
Why?
|
| Vascular Calcification | 1 | 2012 | 8 | 0.090 |
Why?
|
| Infant, Newborn | 3 | 2021 | 828 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 325 | 0.080 |
Why?
|
| Smoking | 1 | 2013 | 373 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2019 | 995 | 0.080 |
Why?
|
| Social Class | 1 | 2011 | 106 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 203 | 0.080 |
Why?
|
| Vitamin D Deficiency | 1 | 2010 | 23 | 0.080 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 653 | 0.080 |
Why?
|
| Stillbirth | 2 | 2021 | 29 | 0.070 |
Why?
|
| Pregnancy | 3 | 2021 | 1555 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 677 | 0.070 |
Why?
|
| Prevalence | 2 | 2021 | 785 | 0.070 |
Why?
|
| Seasons | 2 | 2019 | 114 | 0.070 |
Why?
|
| Cause of Death | 2 | 2018 | 171 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2025 | 186 | 0.050 |
Why?
|
| Physicians | 1 | 2025 | 114 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2025 | 322 | 0.050 |
Why?
|
| Headache | 1 | 2023 | 11 | 0.050 |
Why?
|
| Back Pain | 1 | 2023 | 32 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 317 | 0.050 |
Why?
|
| Prescriptions | 1 | 2023 | 28 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 1058 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2026 | 1186 | 0.050 |
Why?
|
| Outpatients | 1 | 2023 | 99 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 12 | 0.050 |
Why?
|
| Naltrexone | 1 | 2020 | 16 | 0.040 |
Why?
|
| Drug Hypersensitivity | 1 | 2019 | 8 | 0.040 |
Why?
|
| Appendicitis | 1 | 2019 | 14 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2019 | 24 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 42 | 0.040 |
Why?
|
| Pancreatitis | 1 | 2019 | 54 | 0.040 |
Why?
|
| Medicare | 1 | 2020 | 188 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2020 | 167 | 0.040 |
Why?
|
| Respiratory Tract Diseases | 1 | 2018 | 21 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 382 | 0.030 |
Why?
|
| Vaccines, Conjugate | 1 | 2017 | 59 | 0.030 |
Why?
|
| Congenital Abnormalities | 1 | 2017 | 26 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2020 | 248 | 0.030 |
Why?
|
| Bell Palsy | 1 | 2017 | 14 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2017 | 160 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2016 | 12 | 0.030 |
Why?
|
| Infection | 1 | 2016 | 17 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2017 | 112 | 0.030 |
Why?
|
| Fever | 1 | 2016 | 52 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 31 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2015 | 57 | 0.030 |
Why?
|
| Survival Rate | 1 | 2016 | 247 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2015 | 66 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 104 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 198 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2017 | 400 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2015 | 5 | 0.030 |
Why?
|
| Hispanic Americans | 1 | 2017 | 350 | 0.030 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2015 | 99 | 0.030 |
Why?
|
| Epilepsy | 1 | 2014 | 14 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 16 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2016 | 161 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2014 | 261 | 0.030 |
Why?
|
| Maternal Age | 1 | 2014 | 73 | 0.030 |
Why?
|
| Gestational Age | 1 | 2014 | 118 | 0.020 |
Why?
|
| Minority Groups | 1 | 2013 | 99 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 393 | 0.020 |
Why?
|
| Calcitriol | 1 | 2010 | 1 | 0.020 |
Why?
|
| Hypocalcemia | 1 | 2010 | 1 | 0.020 |
Why?
|
| Chronic Kidney Disease-Mineral and Bone Disorder | 1 | 2010 | 1 | 0.020 |
Why?
|
| Hyperphosphatemia | 1 | 2010 | 1 | 0.020 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2010 | 2 | 0.020 |
Why?
|
| Ergocalciferols | 1 | 2010 | 3 | 0.020 |
Why?
|
| Hypercalcemia | 1 | 2010 | 2 | 0.020 |
Why?
|
| Hypophosphatemia | 1 | 2010 | 2 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2010 | 8 | 0.020 |
Why?
|
| Receptors, Calcitriol | 1 | 2010 | 12 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2010 | 8 | 0.020 |
Why?
|
| Fibroblast Growth Factors | 1 | 2010 | 12 | 0.020 |
Why?
|
| Calcinosis | 1 | 2010 | 18 | 0.020 |
Why?
|
| Minerals | 1 | 2010 | 7 | 0.020 |
Why?
|
| Osteoporosis | 1 | 2010 | 73 | 0.020 |
Why?
|
| Vitamin D | 1 | 2010 | 75 | 0.020 |
Why?
|
Concepts
(250)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(45)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->